WAVEMAN · COMPANY

EVGN · Evogene Ltd.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

EVGN

Name: Evogene Ltd. (EVGN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Evogene Ltd.

PHARMA & BIOTECH · AGRICULTURAL CHEMICALS · CIK 0001574565

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

$692.1K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$692.1K over 180 days

+$692.1K over 90 days

more than 86% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

5 funds added or opened last quarter

below 96% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

0.5% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 78% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

RECANATI LEON disclosed a 5%+ stake (5.7%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -56.1%

-56.1%12M

INSIDER BUY13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows a net $692.1K bought by insiders over 180 days, 5 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Evogene Ltd. insiders bought a net $692.1K of stock across 2 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

RECANATI LEON

Director

BUY

2026-08-11

460,000.0

$292.1K

RECANATI LEON

Director

BUY

2026-08-04

800,000.0

$400.0K

2 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

SUSQUEHANNA INTERNATIONAL GROUP, LLP

80,078.0 sh

$33.9K

CITADEL ADVISORS LLC

50,526.0 sh

$21.4K

XTX Topco Ltd

19,404.0 sh

$8.2K

UBS Group AG

10,790.0 sh

$4.7K

Daytona Street Capital LLC

9,253.0 sh

$4.7K

5%+ owners

13D = intent to influence · 13G = passive

RECANATI LEON

ACTIVIST 13D · 2026-08-11

5.7%

L.I.A. Pure Capital Ltd.

ACTIVIST 13D · 2026-07-10

12.61%

Kfir Silberman

ACTIVIST 13D · 2026-07-10

12.61%

Invest Pro Shukai Hon Ltd.

ACTIVIST 13D · 2026-07-10

4.13%

Ron Yair Peled

ACTIVIST 13D · 2026-07-10

4.13%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
GROSS PROFIT	$-241.0K	$3.2M	$1.5M	$766.0K
NET INCOME	$-7.8M	$-18.1M	$-26.0M	$-29.8M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE